Moderna (MRNA) Receivables - Other (2017 - 2025)
Moderna (MRNA) has disclosed Receivables - Other for 9 consecutive years, with $42.0 million as the latest value for Q4 2025.
- Quarterly Receivables - Other fell 28.81% to $42.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.0 million through Dec 2025, down 28.81% year-over-year, with the annual reading at $42.0 million for FY2025, 28.81% down from the prior year.
- Receivables - Other for Q4 2025 was $42.0 million at Moderna, down from $47.0 million in the prior quarter.
- The five-year high for Receivables - Other was $62.0 million in Q2 2023, with the low at $3.0 million in Q1 2022.
- Average Receivables - Other over 5 years is $39.8 million, with a median of $47.0 million recorded in 2025.
- The sharpest move saw Receivables - Other tumbled 62.5% in 2022, then surged 1300.0% in 2023.
- Over 5 years, Receivables - Other stood at $51.0 million in 2021, then decreased by 17.65% to $42.0 million in 2022, then soared by 40.48% to $59.0 million in 2023, then changed by 0.0% to $59.0 million in 2024, then dropped by 28.81% to $42.0 million in 2025.
- According to Business Quant data, Receivables - Other over the past three periods came in at $42.0 million, $47.0 million, and $53.0 million for Q4 2025, Q2 2025, and Q1 2025 respectively.